What are the approved cancer indications for bevacizumab (Avastin), the recommended dosing schedules for each indication, the contraindications, and the monitoring and management recommendations?

Bevacizumab (Avastin): Approved Indications, Dosing, Contraindications, and Monitoring

Bevacizumab is FDA-approved for multiple cancer indications with specific dosing schedules that vary by cancer type and treatment line. The drug must be permanently discontinued for gastrointestinal perforation, tracheoesophageal fistula, grade 4 fistula, necrotizing fasciitis, and grade 3-4 hemorrhage 1.

FDA-Approved Cancer Indications and Dosing

Metastatic Colorectal Cancer (mCRC)

• First-line treatment: 5 mg/kg IV every 2 weeks with bolus-IFL, or 10 mg/kg IV every 2 weeks with FOLFOX4 1
• Second-line treatment (after progression on bevacizumab-containing regimen): 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin chemotherapy 1
• Important limitation: Bevacizumab is NOT indicated for adjuvant treatment of colon cancer 1

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

• First-line treatment: 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel 1
• Critical exclusion: Patients with squamous cell histology should NOT receive bevacizumab due to increased risk of life-threatening hemoptysis 2

Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Stage III/IV following initial surgery:

• 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel for up to 6 cycles, followed by bevacizumab 15 mg/kg every 3 weeks as single agent for total of up to 22 cycles 3, 1

Platinum-resistant recurrent disease:

• 10 mg/kg IV every 2 weeks with paclitaxel, pegylated liposomal doxorubicin, or weekly topotecan 1
• 15 mg/kg IV every 3 weeks with topotecan given every 3 weeks 1

Platinum-sensitive recurrent disease:

• 15 mg/kg IV every 3 weeks with carboplatin/paclitaxel for 6-8 cycles, then bevacizumab alone every 3 weeks until progression 1
• 15 mg/kg IV every 3 weeks with carboplatin/gemcitabine for 6-10 cycles, then bevacizumab alone every 3 weeks until progression 1

Cervical Cancer (Persistent, Recurrent, or Metastatic)

• 15 mg/kg IV every 3 weeks with paclitaxel/cisplatin or paclitaxel/topotecan 1

Recurrent Glioblastoma

• 10 mg/kg IV every 2 weeks as monotherapy 1

Metastatic Renal Cell Carcinoma

• 10 mg/kg IV every 2 weeks with interferon alfa 1

Hepatocellular Carcinoma (Unresectable or Metastatic)

• 15 mg/kg IV every 3 weeks after atezolizumab 1,200 mg IV on same day, until disease progression or unacceptable toxicity 1

Absolute Contraindications and Required Discontinuation

Permanently discontinue bevacizumab for:

• Gastrointestinal perforation (any grade) 1
• Tracheoesophageal fistula (any grade) 1
• Grade 4 fistula or fistula involving any internal organ 1
• Necrotizing fasciitis 1
• Grade 3 or 4 hemorrhage 1
• Hypertensive crisis or hypertensive encephalopathy 4

Withhold bevacizumab for:

• Recent hemoptysis ≥2.5 mL (½ teaspoon) 1
• Any wound healing complications (safety of resumption not established) 1
• At least 28 days before elective surgery 1
• Medically uncontrolled hypertension 4

Avoid bevacizumab in patients with:

• Squamous cell lung cancer histology 2
• ECOG performance status >1 2
• Clinically significant cardiovascular disease 2
• Inadequate organ function 2

Critical Surgical Timing Requirements

Bevacizumab interferes with wound healing and requires strict surgical timing 5, 1:

• Pre-operative: Stop bevacizumab at least 6 weeks (2 half-lives) before elective surgery 5
• Post-operative: Do not restart bevacizumab until at least 28 days after major surgery AND adequate wound healing is confirmed 1
• Studies show wound healing complications increase from 3.4% to 13% when bevacizumab is given during major surgery 5

Monitoring and Management Recommendations

Hypertension Monitoring

Hypertension is the most common adverse event, occurring in 34-55% of patients (grade ≥3 in 6-25%) 4:

• Check blood pressure at baseline and before each dose
• Median time to onset is 2.1 months (range 0-28 months) 4
• 63% of grade ≥3 hypertension occurs within first 6 months 4
• Treat with standard antihypertensive medications
• Permanently discontinue for hypertensive crisis or encephalopathy 4, 1

Hemorrhage Monitoring

• Assess for any bleeding symptoms before each dose
• Permanently discontinue for grade 3-4 hemorrhage 1
• Withhold for hemoptysis ≥2.5 mL 1

Proteinuria Monitoring

• Perform urinalysis before each dose
• If dipstick shows ≥2+ protein, obtain 24-hour urine collection
• Consider dose modification or discontinuation based on severity

Thromboembolic Event Monitoring

• Increased risk of arterial thromboembolic events, especially in patients ≥65 years 6, 7
• Monitor for signs/symptoms of stroke, myocardial infarction, or other arterial events

Gastrointestinal Perforation Surveillance

• Educate patients about symptoms: severe abdominal pain, constipation, vomiting
• Permanently discontinue if perforation occurs 1

Important Clinical Caveats

Continuation beyond progression: Data are insufficient to support continuing bevacizumab with second-line regimens after progression on bevacizumab-containing first-line therapy in colorectal cancer 6, 7. This practice is not recommended.

Combination restrictions: Do not combine bevacizumab with anti-EGFR antibodies (cetuximab or panitumumab) due to increased toxicity without benefit 6, 7, 6.

No rebound effect: Discontinuation of bevacizumab does not cause accelerated tumor progression or increased mortality 5.

Infusion rates: After initial 90-minute infusion, subsequent doses can be safely administered over 30 minutes or at 0.5 mg/kg/min (5 mg/kg over 10 min; 7.5 mg/kg over 15 min) 6, 8.